SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED **PURSUANT TO RULE 13d-2** (Amendment No.)

Proteon Therapeutics, Inc.

(Name of Issuer)

Common Stock, \$0.001 par value per share (Title of Class of Securities)

> 74371L109 (CUSIP Number)

September 25, 2018 (Date of Event Which Requires Filing of this Statement)

Che	ck the appropriate box to designate the rule pursuant to which this Schedule is filed:
□ R	ule 13d-1(b)
⊠ R	ule 13d-1(c)
□ R	ule 13d-1(d)
(1)	The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

			REPORTING PERSONS			
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)					
2	New Leaf Biopharma Opportunities II, L.P. ("Biopharma II")					
2	2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) □ (b) ⊠					
	(a) □ (ַט) ע	$oldsymbol{Z}$			
3	SEC USE C	NLV	<i>-</i>			
3	old ool o	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				
4	CITIZENSI	HIP (OR PLACE OF ORGANIZATION			
	Delaware					
		5	SOLE VOTING POWER			
			1,523,200 shares; except that (i) New Leaf BPO Associates II, L.P. ("NLBA II"), the sole general partner of Biopharma II, may			
			be deemed to have sole power to vote such shares; (ii) New Leaf BPO Management II, L.L.C. ("NLB Management II"), the sole			
			general partner of NLBA II and ultimate general partner of Biopharma II, may be deemed to have sole power to vote such shares; and (iii) each of Ronald M. Hunt ("Hunt"), Vijay K. Lathi ("Lathi"), Liam T. Ratcliffe ("Ratcliffe"), and Isaac Manke			
NU	MBER OF		("Manke") the managing directors of NLB Management II, may be deemed to have shared power to vote such shares.			
9	SHARES	6	SHARED VOTING POWER			
	IEFICIALLY					
O	WNED BY		See response to row 5.			
RE	EACH PORTING	7	SOLE DISPOSITIVE POWER			
	PERSON					
	WITH		1,523,200 shares; except that (i) NLBA II, the sole general partner of Biopharma II, may be deemed to have sole power to			
			dispose of such shares; (ii) NLB Management II, the sole general partner of NLBA II and ultimate general partner of Biopharma			
			II, may be deemed to have sole power to dispose of such shares; and (iii) each of Hunt, Lathi, Ratcliffe, and Manke, the			
	;	8	managing directors of NLB Management II, may be deemed to have shared power to dispose of such shares. SHARED DISPOSITIVE POWER			
		0	SHARED DISPOSITIVE POWER			
			See response to row 7.			
9	AGGREGAT	ГЕ А	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	1,523,200 shares					
10	CHECK IF	ГНЕ	AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)			
11	DEDCEME	OF C	A CC DEDDECENTED DV A MOUNT IN DOLL (0)			
11	PERCENT (JF C	CLASS REPRESENTED BY AMOUNT IN ROW (9)			
	8.6%					
12		EPO	RTING PERSON (SEE INSTRUCTIONS)			
	III OI K	0	111.0121001. (CDD 110110)			
	PN					

1					
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)				
	New Leaf BPO Associates II, L.P.				
2					
	(a) 🗆 (b) 🗵			
3	SEC USE C	NLY			
4	CITIZENSI	HIP C	OR PLACE OF ORGANIZATION		
	Delaware				
		5	SOLE VOTING POWER		
			1,523,200 shares, all of which are owned by Biopharma II; except that (i) NLBA II, the sole general partner of Biopharma II,		
			may be deemed to have sole power to vote such shares; (ii) NLB Management II, the sole general partner of NLBA II and		
			ultimate general partner of Biopharma II, may be deemed to have sole power to vote such shares; and (iii) each of Hunt, Lathi,		
N.T.T	IMPER OF		Ratcliffe, and Manke, the managing directors of NLB Management II, may be deemed to have shared power to vote such shares.		
	JMBER OF SHARES	6	SHARED VOTING POWER		
	NEFICIALLY				
	WNED BY		See response to row 5.		
Ü	EACH	7	SOLE DISPOSITIVE POWER		
RF	EPORTING				
]	PERSON		1,523,200 shares, all of which are owned by Biopharma II; except that (i) NLBA II, the sole general partner of Biopharma II,		
	WITH		may be deemed to have sole power to dispose of such shares; (ii) NLB Management II, the sole general partner of NLBA II and		
			ultimate general partner of Biopharma II, may be deemed to have sole power to dispose of such shares; and (iii) each of Hunt,		
			Lathi, Ratcliffe, and Manke, the managing directors of NLB Management II, may be deemed to have shared power to dispose of		
			such shares.		
		8	SHARED DISPOSITIVE POWER		
. 1			See response to row 7.		
9	AGGREGAT	ГЕ А	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	1,523,200 shares				
10	10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				
11	PERCENT (JF C	LASS REPRESENTED BY AMOUNT IN ROW (9)		
	8.6%				
12	TYPE OF R	EPO:	RTING PERSON (SEE INSTRUCTIONS)		
	PN				

1				
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)			
	N. J. (DDO) (W.L.C.			
	New Leaf BPO Management II, L.L.C.			
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)				
	(a) 🗆 (b) 🛭		
	CEC LICE C	NTT X	7	
3	SEC USE C	INLY		
4	CITIZENCI	JID (OR PLACE OF ORGANIZATION	
4	CITIZENSI	IIF (OK PLACE OF OKGANIZATION	
	Delaware			
	Belaware	5	SOLE VOTING POWER	
			1,523,200 shares, all of which are owned by Biopharma II; except that (i) NLBA II, the sole general partner of Biopharma II,	
			may be deemed to have sole power to vote such shares; (ii) NLB Management II, the sole general partner of NLBA II and	
			ultimate general partner of Biopharma II, may be deemed to have sole power to vote such shares; and (iii) each of Hunt, Lathi,	
			Ratcliffe, and Manke, the managing directors of NLB Management II, may be deemed to have shared power to vote such shares.	
	JMBER OF SHARES	6	SHARED VOTING POWER	
	NEFICIALLY			
	WNED BY		See response to row 5.	
	EACH	7	SOLE DISPOSITIVE POWER	
RE	EPORTING		4 500 000 l	
]	PERSON		1,523,200 shares, all of which are owned by Biopharma II; except that (i) NLBA II, the sole general partner of Biopharma II,	
	WITH		may be deemed to have sole power to dispose of such shares; (ii) NLB Management II, the sole general partner of NLBA II and ultimate general partner of Biopharma II, may be deemed to have sole power to dispose of such shares; and (iii) each of Hunt,	
			Lathi, Ratcliffe, and Manke, the managing directors of NLB Management II, may be deemed to have shared power to dispose of	
			such shares.	
	,	8	SHARED DISPOSITIVE POWER	
		U	Oliman Diol Gollive Towner	
			See response to row 7.	
9	AGGREGAT	ΓΕ Α	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	1,523,200 shares			
10	CHECK IF	ГНЕ	AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	
11	DEDCENT	OF C	LASS REPRESENTED BY AMOUNT IN ROW (9)	
11	PERCENT (JF C	LASS REPRESENTED BY AMOUNT IN ROW (9)	
	8.6%			
12		EPO	RTING PERSON (SEE INSTRUCTIONS)	
			(
	00			

1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)			
	Ronald M. I			
2		IE A (b) □	PPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) ☑	
3	SEC USE C	NLY		
4	CITIZENSI	HIP (OR PLACE OF ORGANIZATION	
	United State	es cit	izen	
	omica otati	5	SOLE VOTING POWER	
			See response to row 6.	
	·	6	SHARED VOTING POWER	
NI	JMBER OF		1,523,200 shares, all of which are owned by Biopharma II; except that (i) NLBA II, the sole general partner of Biopharma II,	
	SHARES		may be deemed to have sole power to vote such shares; (ii) NLB Management II, the sole general partner of NLBA II and	
	NEFICIALLY		ultimate general partner of Biopharma II, may be deemed to have sole power to vote such shares; and (iii) each of Hunt, Lathi,	
O	WNED BY		Ratcliffe, and Manke, the managing directors of NLB Management II, may be deemed to have shared power to vote such shares. SOLE DISPOSITIVE POWER	
	EACH	7	SOLE DISPOSITIVE POWER	
	EPORTING		See response to row 8.	
]	PERSON	8	SHARED DISPOSITIVE POWER	
	WITH	U	STRIKED DIST COTTIVE TOWER	
			1,523,200 shares, all of which are owned by Biopharma II; except that (i) NLBA II, the sole general partner of Biopharma II,	
			may be deemed to have sole power to dispose of such shares; (ii) NLB Management II, the sole general partner of NLBA II and	
			ultimate general partner of Biopharma II, may be deemed to have sole power to dispose of such shares; and (iii) each of Hunt,	
			Lathi, Ratcliffe, and Manke, the managing directors of NLB Management II, may be deemed to have shared power to dispose of	
			such shares.	
9	AGGREGAT	ГЕ А	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	1,523,200 sh	ares		
10			AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	
			(-,	
11	PERCENT (OF C	LASS REPRESENTED BY AMOUNT IN ROW (9)	
4.0	8.6%	EDC	DEVICE DED CON (CEE INCERNICATIONS)	
12	TYPE OF R	EPO	RTING PERSON (SEE INSTRUCTIONS)	
	IN			
	1			

1	NAMES OF REPORTING PERSONS			
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)			
	Vijay K. Lathi			
2			PPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)	
		њл Ъ) [∑	· · · · · · · · · · · · · · · · · · ·	
	(a) 🗆 (ט) ע		
3	SEC USE C	NLY	7	
4	CITIZENSI	HIP (OR PLACE OF ORGANIZATION	
	United State	es cit	izen	
	Office State	5	SOLE VOTING POWER	
		3	SOLE VOTING FOWER	
			See response to row 6.	
		6	SHARED VOTING POWER	
NIT	D (DED OF		1,523,200 shares, all of which are owned by Biopharma II; except that (i) NLBA II, the sole general partner of Biopharma II,	
	JMBER OF		may be deemed to have sole power to vote such shares; (ii) NLB Management II, the sole general partner of NLBA II and	
	SHARES		ultimate general partner of Biopharma II, may be deemed to have sole power to vote such shares; and (iii) each of Hunt, Lathi,	
	NEFICIALLY		Ratcliffe, and Manke, the managing directors of NLB Management II, may be deemed to have shared power to vote such shares.	
O	WNED BY	7	SOLE DISPOSITIVE POWER	
	EACH	,	SOLL DISTOSTIVE TOWER	
	EPORTING		S-2	
PERSON			See response to row 8.	
	WITH	8	SHARED DISPOSITIVE POWER	
			1,523,200 shares, all of which are owned by Biopharma II; except that (i) NLBA II, the sole general partner of Biopharma II,	
			may be deemed to have sole power to dispose of such shares; (ii) NLB Management II, the sole general partner of NLBA II and	
			ultimate general partner of Biopharma II, may be deemed to have sole power to dispose of such shares; and (iii) each of Hunt,	
			Lathi, Ratcliffe, and Manke, the managing directors of NLB Management II, may be deemed to have shared power to dispose of	
			such shares.	
9	AGGREGAT	ΓF. A	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
3	1100112011			
	1,523,200 sh	aroc		
10			AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	
10	CHECK IF	IHE	AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	
	_			
11	PERCENT (OF C	LASS REPRESENTED BY AMOUNT IN ROW (9)	
	8.6%			
12		E₽∩	RTING PERSON (SEE INSTRUCTIONS)	
12	TILOTK	Li U	MINO I EROOM (DEE MOTROCITORO)	
	IN			
	IN			

1	NAMES OF REPORTING PERSONS			
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)			
	Liam T. Ratcliffe			
2			PPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)	
		њ л Ъ) [∑		
	(a) 🗆 (ט) ע		
3	SEC USE C	NLY	7	
4	CITIZENSI	HIP (OR PLACE OF ORGANIZATION	
	United State	e cit	izen	
	Office State	5	SOLE VOTING POWER	
		5	SOLE VOTING POWER	
			See response to row 6.	
		6	SHARED VOTING POWER	
	n (DED OF		1,523,200 shares, all of which are owned by Biopharma II; except that (i) NLBA II, the sole general partner of Biopharma II,	
	JMBER OF		may be deemed to have sole power to vote such shares; (ii) NLB Management II, the sole general partner of NLBA II and	
	SHARES		ultimate general partner of Biopharma II, may be deemed to have sole power to vote such shares; and (iii) each of Hunt, Lathi,	
	NEFICIALLY		Ratcliffe, and Manke, the managing directors of NLB Management II, may be deemed to have shared power to vote such shares.	
O	WNED BY	7	SOLE DISPOSITIVE POWER	
	EACH	,	SOLL DISTOSTIVE TOWER	
	EPORTING		S-2	
1	PERSON		See response to row 8.	
	WITH	8	SHARED DISPOSITIVE POWER	
			1,523,200 shares, all of which are owned by Biopharma II; except that (i) NLBA II, the sole general partner of Biopharma II,	
			may be deemed to have sole power to dispose of such shares; (ii) NLB Management II, the sole general partner of NLBA II and	
			ultimate general partner of Biopharma II, may be deemed to have sole power to dispose of such shares; and (iii) each of Hunt,	
			Lathi, Ratcliffe, and Manke, the managing directors of NLB Management II, may be deemed to have shared power to dispose of	
			such shares.	
9	AGGREGAT	ΓF. A	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	1100111011	1	ENGLISHED DI ENGLISH ONTHO LENGTH	
	1,523,200 sh	oroc		
10				
10	CHECK IF	IHE	AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	
11	PERCENT (OF C	LASS REPRESENTED BY AMOUNT IN ROW (9)	
	8.6%			
12		FD∩	RTING PERSON (SEE INSTRUCTIONS)	
14	TIFEOFK	LFU	KIIIAO I EKOON (DEE INDIKOCIIONO)	
	TNI			
	IN			

1	NAMES OF REPORTING PERSONS			
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)			
	Isaac Manke			
2			PPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)	
2		ъ ъ	· · · · · · · · · · · · · · · · · · ·	
	(a) 🗆 (ַט) צ		
3	SEC USE C	NLY	7	
4	CITIZENSI	HIP (OR PLACE OF ORGANIZATION	
	United State	es cit	izen	
	Office State	5	SOLE VOTING POWER	
		5	SOLE VOTING POWER	
			See response to row 6.	
		6	SHARED VOTING POWER	
	n (DED OF		1,523,200 shares, all of which are owned by Biopharma II; except that (i) NLBA II, the sole general partner of Biopharma II,	
	JMBER OF		may be deemed to have sole power to vote such shares; (ii) NLB Management II, the sole general partner of NLBA II and	
	SHARES		ultimate general partner of Biopharma II, may be deemed to have sole power to vote such shares; and (iii) each of Hunt, Lathi,	
	NEFICIALLY		Ratcliffe, and Manke, the managing directors of NLB Management II, may be deemed to have shared power to vote such shares.	
O	WNED BY	7	SOLE DISPOSITIVE POWER	
	EACH	,	SOLL DISTOSTIVE TOWER	
	EPORTING		S-2	
PERSON			See response to row 8.	
	WITH	8	SHARED DISPOSITIVE POWER	
			1,523,200 shares, all of which are owned by Biopharma II; except that (i) NLBA II, the sole general partner of Biopharma II,	
			may be deemed to have sole power to dispose of such shares; (ii) NLB Management II, the sole general partner of NLBA II and	
			ultimate general partner of Biopharma II, may be deemed to have sole power to dispose of such shares; and (iii) each of Hunt,	
			Lathi, Ratcliffe, and Manke, the managing directors of NLB Management II, may be deemed to have shared power to dispose of	
			such shares.	
9	AGGREGAT	ΓF. A	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	ricord.		and on I be the real bull of the real real real real real real real rea	
	1,523,200 sh	arac		
10				
10	CHECK IF	IHE	AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	
11	PERCENT (OF C	LASS REPRESENTED BY AMOUNT IN ROW (9)	
	8.6%			
12		FD∩	RTING PERSON (SEE INSTRUCTIONS)	
14	I I F L OF K	LFU	KIIIAO I EKOON (DEE INDIKOCIIONO)	
	TAT			
	IN			

Schedule 13G

Item 1(a). Name of Issuer:

Proteon Therapeutics, Inc. (the "Issuer").

Item 1(b). Address of Issuer's Principal Executive Offices:

200 West Street Waltham, MA 02451

Item 2(a). Name of Persons Filing:

This joint statement on Schedule 13G is being filed by New Leaf Biopharma Opportunities II, L.P. ("Biopharma II"), New Leaf BPO Associates II, L.P. ("NLBA II") and New Leaf BPO Management II, L.L.C. ("NLB Management II" and together with Biopharma II and NLBA II, the "Reporting Entities") and Ronald M. Hunt ("Hunt"), Vijay K. Lathi ("Lathi"), Liam T. Ratcliffe ("Ratcliffe"), and Isaac Manke ("Manke" and, together with Hunt, Lathi, and Ratcliff, the "Managing Directors"). The Reporting Entities and the Managing Directors collectively are referred to as the "Reporting Persons".

NLBA II is the sole general partner of Biopharma II and may be deemed to have sole power to vote and sole power to dispose of shares of the Issuer directly owned by Biopharma II. NLB Management II is the sole general partner of NLBA II and ultimate general partner of Biopharma II and may be deemed to have sole power to vote and sole power to dispose of shares of the Issuer directly owned by Biopharma II. Each of Hunt, Lathi, Ratcliffe and Manke are the managing directors of NLB Management II and may be deemed to have shared power to vote and shared power to dispose of shares of the Issuer directly owned by Biopharma II.

Item 2(b). Address of Principal Business Office or, if None, Residence:

The address of the principal business office of Biopharma II, NLBA II, NLB Management II, Hunt, Ratcliffe and Manke is New Leaf Venture Partners, Times Square Tower, 7 Times Square, Suite 3502, New York, NY 10036.

The address of the principal business office of Lathi is New Leaf Venture Partners, 1200 Park Place, Suite 300, San Mateo, CA 94043.

Item 2(c). <u>Citizenship</u>:

Each of Biopharma II and NLBA II is a limited partnership organized under the laws of the State of Delaware.

NLB Management II is a limited liability company organized under the laws of the State of Delaware.

Each Managing Director is a citizen of the United States.

Item 2(d). <u>Title of Class of Securities</u>:

Common Stock, \$0.001 par value per share ("Common Stock").

Item 2(e). <u>CUSIP Number</u>:

74371L109

Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

Not applicable.

Item 4. Ownership.

(a) Amount beneficially owned:

See line 9 of cover sheets. Biopharma II is the record owner of the 1,523,200 shares of Common Stock (the "Biopharma II Shares"). As the sole general partner of Biopharma II, NLBA II may be deemed to own beneficially the Biopharma II Shares. As the sole general partner of NLBA II and ultimate general partner of Biopharma II, NLB Management II may be deemed to own beneficially the Biopharma II Shares. As the individual managing directors of NLB Management II, each of the Managing Directors also may be deemed to own beneficially the Biopharma II Shares.

(b) Percent of class:

See Line 11 of cover sheets. The percentages set forth on the cover sheet for each Reporting Person are calculated based on 17,726,713 shares of Common Stock reported by the Issuer to be outstanding as of July 31, 2018 on Form 10-Q as filed with the Securities and Exchange Commission on August 7, 2018.

- (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote: see line 5 of cover sheets.
 - (ii) Shared power to vote or to direct the vote: see line 6 of cover sheets.
 - (iii) Sole power to dispose or to direct the disposition of: see line 7 of cover sheets.
 - (iv) Shared power to dispose or to direct the disposition of: see line 8 of cover sheets.

Each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record and to the extent of their pecuniary interest therein.

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Under certain circumstances set forth in the limited partnership agreements of each of Biopharma II and NLBA II, and the limited liability company agreement of NLB Management II, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by each such entity of which they are a partner or member, as the case may be.

Item 7. <u>Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.</u>

Not applicable.

Item 8. <u>Identification and Classification of Members of the Group</u>.

Not applicable.

Item 9. <u>Notice of Dissolution of Group</u>.

Not applicable.

Item 10. <u>Certification</u>.

Not applicable.

Material to be Filed as Exhibits.

Exhibit 1 – Agreement Regarding Joint Filing of Schedule 13G.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: November 6, 2018

NEW LEAF BIOPHARMA OPPORTUNITIES II, L.P.

By: NEW LEAF BPO ASSOCIATES II, L.P.

Its General Partner

By: NEW LEAF BPO MANAGEMENT II, L.L.C.

Its General Partner

By: /s/ Craig L. Slutzkin

Craig L. Slutzkin Chief Financial Officer

NEW LEAF BPO ASSOCIATES II, L.P.

By: NEW LEAF BPO MANAGEMENT II, L.L.C.

Its General Partner

By: /s/ Craig L. Slutzkin

Craig L. Slutzkin Chief Financial Officer

NEW LEAF BPO MANAGEMENT II, L.L.C.

By: /s/ Craig L. Slutzkin

Craig L. Slutzkin

Chief Financial Officer

Vijay K. Lathi

3 3

Ronald M. Hunt

Liam T. Ratcliffe

*

Isaac Manke

/s/ Craig L. Slutzkin

* Craig L. Slutzkin

As attorney-in-fact

* This Schedule 13G was executed by Craig L. Slutzkin on behalf of the individuals listed above pursuant to Powers of Attorney. Note that copies of the applicable Powers of Attorney are already on file with the appropriate agencies.

AGREEMENT REGARDING JOINT FILING OF SCHEDULE 13G

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Proteon Therapeutics, Inc.

Date: November 6, 2018

	OPPORTUNITIES	II I D

By: NEW LEAF BPO ASSOCIATES II, L.P. Its General Partner

By: NEW LEAF BPO MANAGEMENT II, L.L.C. Its General Partner

By: /s/ Craig L. Slutzkin
Craig L. Slutzkin
Chief Financial Officer

NEW LEAF BPO ASSOCIATES II, L.P.

By: NEW LEAF BPO MANAGEMENT II, L.L.C. Its General Partner

By: /s/ Craig L. Slutzkin
Craig L. Slutzkin
Chief Financial Officer

Isaac Manke

NEW LEAF BPO MANAGEMENT II, L.L.C.

By: /s/ Craig L. Slutzkin
Craig L. Slutzkin
Chief Financial Officer

*
Vijay K. Lathi

*
Ronald M. Hunt

*
Liam T. Ratcliffe

/s/ Craig L. Slutzkin

Craig L. Slutzkin As attorney-in-fact

* This Schedule 13G was executed by Craig L. Slutzkin on behalf of the individuals listed above pursuant to Powers of Attorney. Note that copies of the applicable Powers of Attorney are already on file with the appropriate agencies.